Lioe-Fee de Geus-Oei (1971) is a Professor of Radiology, in particular Nuclear Medicine, at LUMC, where she is Group Leader of the Nuclear Medicine Research Group, Member of the Core Management Team "Fundamental Technologies for Imaging and Omics”, chairwoman of the Education Management Team, member of the Radiology Management Team and of the Group Leader Board. In addition, she is part-time clinical Professor of Molecular Imaging, Innovation and Translation at the University of Twente and Medical Delta Professor, embedded in the Department of Radiation Science & Technology, at Delft University of Technology. She is also on the Steering Committee of the European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group in Brussels, on the Guideline and Publication Council of the European Association of Nuclear Medicine (EANM) in Vienna and on the National Science Agenda 2024-2028 (NWA-NVNG) writing group.

More information about Lioe-Fee de Geus-Oei

Lioe-Fee de Geus-Oei (1971) is a Professor of Radiology, in particular Nuclear Medicine, at LUMC, where she is Group Leader of the Nuclear Medicine Research Group, Member of the Core Management Team "Fundamental Technologies for Imaging and Omics”, chairwoman of the Education Management Team, member of the Radiology Management Team and of the Group Leader Board. In addition, she is part-time clinical Professor of Molecular Imaging, Innovation and Translation at the University of Twente and Medical Delta Professor, embedded in the Department of Radiation Science & Technology, at Delft University of Technology. She is also on the Steering Committee of the European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group in Brussels, on the Guideline and Publication Council of the European Association of Nuclear Medicine (EANM) in Vienna and on the National Science Agenda 2024-2028 (NWA-NVNG) writing group.

Nuclear Medicine

Her line of research makes use of the most powerful newest generation multi-modality functional and molecular imaging tools, translating basic science into clinical benefit. It aims at providing a rationale on which optimal treatment strategies can be designed. The research focusses on improving personalized patient management through the upfront implementation of predictive imaging biomarkers. Methods need to be developed that will help to reduce morbidity, efforts and costs by early identification of ineffective treatment in non-responders. This is not only important for the individual patient, but is also of significant societal and economic relevance, since the costs of several therapies are high and effective in just a fraction of patients. Use of these techniques can have an impact on drug and treatment development processes, patient selection in early phases of treatment, and on implementing new drugs and new treatment strategies into clinical care. The molecular imaging tools can be valuable at several stages of development of treatments, to get insight in its mechanisms of action. They have great potential to generate significant cost savings that can fund their application. These research concepts will focus primarily on oncological research, but also perfectly fit into infectiology, cardiovascular, neurology research, which are the other tracks at LUMC. This type of research, studying and validating quantitative molecular imaging methods and advanced PET-applications with the ultimate goal to develop tools to be used as predictive and prognostic imaging biomarkers, continued in the projects of all of her 34 PhD students (24 completed and 10 ongoing PhD projects) at LUMC, Radboudumc, the University of Twente and Delft University of Technology. This translational line of research bridges preclinical with clinical research and aims to bring new technical innovations to the bedside and corresponds to the topics of the NVNG National Science Agenda 2024-2028.

Academic career

Lioe-Fee obtained her PhD on November 19, 2007, at Radboud University, with a dissertation entitled "Characterization of Malignancy with FDG-PET". Lioe-Fee is appointed as (full) professor at three Universities: University of Twente (since 2013), Leiden University (since 2015), and Delft University of Technology (since 2022). Her first inaugural lecture was on October 30, 2014, entitled "The future of imaging mapped out?". Her second inaugural lecture was on December 19, 2016, entitled "PET: tool of wonder and limitless imagination" and her third inauguration took place on November 15, 2022.

Lioe-Fee has authored over 250 scientific publications, published 11 textbook chapters, and 260 scientific abstracts. She has delivered more than 100 invited lectures at (inter)national conferences, and approximately 70 interviews/podcasts with Lioe-Fee have been published in popular media, newspapers, radio, and TV. She obtained 20 prestigious research grants (including NWO-ZonMW, KWF, STW, EU Horizon) as a project leader, work package leader or co-applicant to fund her scientific work. Lioe-Fee serves as a reviewer for 25 scientific journals and five different funding agencies (including NWO-Vici, ZonMw-NWO and KWF). She is BROK (Basic Course in Regulations & Organization for Clinical researchers) and BKO (Basic Qualification in Education) certified. Lioe-Fee has received ten honours and awards, a.o. in 2021 she received the best promotor of the year award at LUMC.

In addition to her daily work, Lioe-Fee has always taken on many subsidiary positions. Since 2016-she has been a board member of the Executive Board and Steering Committee of the European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group in Brussels, and she has been a member of the Oncology and Theranostics committee (2017-2023) and the Guideline and Publication Council (since 2024) of the European Association of Nuclear Medicine (EANM) in Vienna. In this capacity, she chaired multiple international guideline committees, aiming for worldwide standardization of diagnosis and therapy, and to establish evidence-based practices, quality, and safety standards. Lioe-Fee gained significant leadership experience between 2013-2017 when she was the chair of the Dutch Society for Nuclear Medicine (approximately 750 members). During this time, she successfully managed the merger between Radiology and Nuclear Medicine training programs and initiated a powerful lobby in The Hague to accelerate the decision-making process for building a new high-flux reactor in Petten to ensure the current and future production and availability of medical isotopes worldwide. She also served as a member of the scientific advisory committee of Cyclotron BV (2017-2021), Amsterdam. She is/was an editor and chief editor of several scientific journals (BJR, Oncology Up To Date, TVNG, AJNM, JTD, Diagnostics), leading large editorial teams. She has organized many symposia and conferences, acting as the client of congress bureaus, where her content knowledge and organizational skills were valuable. As the Director of the Nuclear Medicine training Program at Radboudumc (2011-2014), she led a group of eight residents in Nuclear Medicine, and currently she is the nuclear medicine common trunk supervisor at LUMC. She has completed various management and leadership courses and programs, Media Training, and in 2009 she was selected to follow the Female career development program, program for female top talent.

Lioe-Fee is married to Wim de Geus and together they have two daughters Daphne (2001) and Leonoor (2004).

Honours and Awards

1. Award for Outstanding Performance, European Medical Students’ Association International Scientific Symposium, Prague, Czech Republic (1994)
2. Marie Curie Young Investigator Congress Grant, European Association of Nuclear Medicine, Copenhagen, Denmark (2007)
3. EANM Young Investigator of the Year Award (2009),
4. Selected to participate in the ‘Female career development program for female top talent’ at Radboudumc (2009-2010)
5. Invited Highlights Lecturer at the European Association of Nuclear Medicine Congress (EANM), Birmingham, UK (2011)
6. Mother of two wonderful daughters (2001 and 2004)

Grants and other funding

1. 2017 Principal Investigator: NWO-ZonMW research grant: HOlmium radioembolization as adjuvant treatment to Radiofrequency Ablation for Early STage Hepatocellular carcinoma (HORA EST HCC): a phase I dose-finding study
2. 2017 Co-Principal Investigator: The neurochemical basis of goal-directed behavior. Funding Body FSW Leiden University
3. 2016 Work Package Leader: Horizon2020 grant: PAMMOTH: Photoacoustic Mammography beyond the Horizon’
4. 2016 GE research grant: Quantitative SPECT/CT studies for therapy monitoring and therapy guidance in patients with locally advanced breast cancer
5. 2015 Consortium Team Member STW-Perspectief programma: P14-19: Radiomics - Non-invasive STRatification of Tissue heterogeneity for personalized medicine – Radiomics STRaTegy
6. 2015 Philips research grant: Radiomics in Osteosarcoma
7. 2015 Siemens research grant: Addition of gated CT to HD-Chest based PET respiratory gating
8. 2015 Grant Rivierduinen GGZ Leiden: Dopaminerg functioneren bij autisme
9. 2014 Principal Investigator: KWF-grant: Efficacy of FDG-PET in the Evaluation of Cytological Indeterminate Thyroid nodules prior to surgery (EfFECTS): a multicentre cost-effectiveness study
10. 2013 Co-applicant: Repetitive 4D-FDG-PET/CT imaging in advanced stage NSCLC patients undergoing individually escalated (chemo) radiotherapy. Funding Body RUNMC Research Institute for Oncology Junior investigators grant
11. 2012 Principal investigator: 4D-training: Op weg naar Doelmatigheid in Diagnostiek in een Didactische Digitale samenwerkingsomgeving. Funding body: UMCN Resident Medical Education Innovation Fund
12. 2010 Principal Investigator: MIBG scan and Strain Echocardiography in the detection of subclinical cardiovascular effects after (neo)adjuvant breast cancer treatment. Funded by Cephalon; Merck Sharp & Dohme; Sanofi-Aventis; GE Healthcare

Activities